2025 FDA approvals FDA Removes 12 Peptides from 503A Category 2 Newtropin The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Launches Framework to Accelerate Individualized Therapies for Ultra Rare Diseases 2026 OncoDaily Dihexa 10mg Capsules Cognitive Research Support Peptide Pure Bio Labs The 2026 Biologics Wave: Which Innovations Will Break Through? Contract Pharma